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Abstract
A phase 2a RTS,S/AS malaria vaccine trial, conducted previously at the Walter Reed Army Institute of Research, conferred
sterile immunity against a primary challenge with infectious sporozoites in 40% of the 80 subjects enrolled in the study. The
frequency of Plasmodium falciparum circumsporozoite protein (CSP)-specific CD4
+ T cells was significantly higher in
protected subjects as compared to non-protected subjects. Intrigued by these unique vaccine-related correlates of
protection, in the present study we asked whether RTS,S also induced effector/effector memory (TE/EM) and/or central
memory (TCM) CD4
+ T cells and whether one or both of these sub-populations is the primary source of cytokine production.
We showed for the first time that PBMC from malaria-non-exposed RTS,S-immunized subjects contain both TE/EM and TCM
cells that generate strong IL-2 responses following re-stimulation in vitro with CSP peptides. Moreover, both the frequencies
and the total numbers of IL-2-producing CD4
+ TE/EM cells and of CD4
+ TCM cells from protected subjects were significantly
higher than those from non-protected subjects. We also demonstrated for the first time that there is a strong association
between the frequency of CSP peptide-reactive CD4
+ T cells producing IL-2 and the titers of CSP-specific antibodies in the
same individual, suggesting that IL-2 may be acting as a growth factor for follicular Th cells and/or B cells. The frequencies of
CSP peptide-reactive, TNF-a-producing CD4
+ TE/EM cells and of CD4
+ TE/EM cells secreting both IL-2 and TNF-a were also
shown to be higher in protected vs. non-protected individuals. We have, therefore, demonstrated that in addition to TNF-a,
IL-2 is also a significant contributing factor to RTS,S/AS vaccine induced immunity and that both TE/EM and TCM cells are
major producers of IL-2.
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Introduction
Immunologically based resistance against many pathogens is
often multi-factorial and involves both cellular and Ab mediated
mechanisms. Protracted protection, therefore, requires the gener-
ation and maintenance of Ag-specific memory T and B cell
responses. In this regard, CD4
+ T cells may be considered as
central mediators of protective immunity because they not only
help to promote CD8
+ T cell and B cell immune responses, but
they also provide their own necessary effector function [1,2].
Although there have been many studies in humans on the capa-
city of various vaccines to induce and maintain memory T cell
responses against viral and other diseases [3,4,5], there has been
only limited analyses of memory T cell responses induced by
vaccines against protozoan pathogens such as Plasmodium falciparum
(Pf) malaria, a disease that causes over one million deaths annually.
It is clear, however, that memory T cell responses to pre-erythrocytic
stages are not readily detectable in subjects naturally exposed to
malaria infection [6]. One of the goals of a successful anti-malaria
vaccine, therefore, is to circumvent this problem and to promote the
induction of long-lived memory T cell responses against re-infection.
RTS,S, which consists of the repeat (R) and C-terminal region
of the Pf major circumsporozoite protein (CSP) fused to the surface
(S) Ag of Hepatitis B virus and co-expressed with free S Ag [7], is
currently the only sub-unit vaccine that provides protection against
malaria. The RTS,S/AS vaccine confers sterile protection in
approximately 40% of malaria naı ¨ve subjects exposed to experi-
mental challenge with Pf sporozoites [8]. In clinical trials in infants
and children living in malaria endemic regions in sub-Saharan
Africa, RTS,S/AS was shown to protect 30% [9] to 66% [10] of
young children against first or only episode of clinical malaria,
with clinical efficacy extending up to 43 months following vac-
cination [11]. The vaccine is currently being tested in a phase III
trial involving 11 sites in 7 countries in East and West Africa.
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e20775A phase 2a RTS,S/AS vaccine trial [8] was conducted at the
Walter Reed Army Institute of Research involving 80 subjects.
Sterile immunity against a primary challenge with infectious
sporozoites was observed in 40% of individuals. Analyses of Pf
CSP-specific cellular responses demonstrated that on the day of
challenge the frequency of CSP peptide-reactive CD4
+ T cells
producing any combination of 2 or more of the following bio-
markers: IL-2, TNF-a or IFN-c and CD40L, was significantly
higher in protected subjects as compared to non-protected sub-
jects. However, we did not address whether the RTS,S/AS
vaccine induced memory CD4
+ T cells and if these memory cells
might be associated with protection. The RTS,S/AS vaccine trial
affords a particularly unique opportunity for studying memory T
cells: a large cohort of immunized protected and non-protected
subjects; samples of peripheral blood mononuclear cells (PBMC)
from multiple time points of vaccination, including baseline as well
as samples following immunizations and challenge.
It is now well established that Ag-experienced CD4
+ T cells
form discrete sub-populations of memory cells that include long-
lived, self-renewing CD45RO
+CCR7
+ T central memory (TCM)
cells and relatively short-lived CD45RO
+CCR7
2 T effector/
effector memory (TE/EM) cells [5]. For viral infections, it has been
demonstrated that TCM cells produce predominately IL-2 while
TE/EM cells secrete primarily IFN- c [12,13,14]. The relative
amounts of cytokines produced by these two populations of cells,
however, may depend on the nature of the vaccine, the strength
and persistence of the antigenic signal, as well as other factors.
In the present study, we asked whether the RTS,S vaccine
induces CSP-specific CD4
+ TE/EM and/or CD4
+ TCM and if these
populations produced similar or distinct cytokine responses and
finally whether the cytokine profile of one or both of these sub-
populations could serve as an immune correlate of protection
against experimental challenge with Pf sporozoites. Our results
demonstrated for the first time that PBMC from RTS,S-immu-
nized subjects contain both TE/EM and TCM cells that generate
strong IL-2 responses following re-stimulation in vitro with CSP
peptides. Moreover, both the frequencies and the total numbers of
IL-2-producing CD4
+ TE/EM cells and of IL-2-producing CD4
+
TCM cells from protected subjects were significantly higher than
those from non-protected subjects. We also demonstrated for the
first time that there is a strong association between the frequency
of IL-2-producing CD4
+ T cells and the titers of CSP-specific
antibodies in the same individual, suggesting that IL-2 may
contribute to protection by promoting both cellular and humoral
immune responses.
Materials and Methods
Study protocol
The study protocol for the phase 2a double-blind, randomized,
challenge trial of the RTS,S/AS vaccine conducted at the Walter
Reed Army Institute of Research has been described previously [8].
Briefly, 80 healthy malaria-naı ¨ve adults received RTS,S/AS at 0, 1
and 2 mo, and then underwent challenge with P. falciparum infected
mosquitoes. PBMC were collected at pre-immunization (Pre),
2 wk post 2
nd immunization (Po2), 2 wk post 3
rd immunization
(Po3)=day of challenge (DOC), and 2 mo post challenge (PoCh).
Ethics Statement
A written informed consent was provided by study participants
and/or their legal guardians. The study protocol was approved by
the WRAIR Human Use Review Committee and the US Army
Medical Research and Materiel Command’s Human Subjects
Research and Review Board (Fort Detrick, Maryland).
PBMC collection
PBMC were isolated as described previously [8] and maintained
in liquid nitrogen until use.
Antigens
Pf CSP peptides (Alpha Diagnostics, San Antonio, TX) cor-
responding to the C-terminal of the CSP region of RTS,S
consisted of two contiguous peptides designated P2, the 44 a.a.
peptide EEPSDKHIKEYLNKIQNSLSTEWSPCSVTCGNGIQ-
VRIKPGSAN and P4, the 35 a.a. peptide KPKDELDYANDI-
EKKICKMEKCSSVFNVVNSSIGL.
Intracellular cytokine staining
PBMC from all time points for a single individual were analyzed
in a single assay. Typically, PBMC from one protected and one
non-protected subject were examined per assay. Briefly, PBMC
were washed twice and re-suspended in culture medium consisting
of RPMI 1640 supplemented with 100 IU/ml penicillin, 100 mg/
ml streptomycin, 8 mM glutamax, 1 mM nonessential a.a., 1 mM
sodium pyruvate, and 50 mM 2-ME and containing 20% human
AB serum (Gemini Bioproducts; Woodland CA). The cells were
then stimulated for 2 h in 96 well U-bottom bottom plates with 2
long contiguous CSP peptides (at a final concentration 20 mg/ml
of each peptide per well) in the presence of 1 mg/ml anti-CD28
(BD Pharmingen) and 1 mg/ml anti-CD49d (BD Pharmingen). In
order to capture the CD4
+ TCM cell phenotype prior to in vitro Ag
stimulation, anti-CCR7-PE (0.15 mg/ml; R&D Systems) was also
included in the culture medium [15]. For each sample/stimulant
combination 2610
5 cells were added to each of eight wells of the
culture plate. GolgiPlug (BD Pharmingen), at a final concentra-
tion 1 mg/ml per well, was added for the last 16 h of culture.
A negative (anti-human CD28 and CD49d) and a positive
[staphylococcal enterotoxin B, 1 mg/ml; (Sigma-Aldrich)] control
were included in each assay. After incubation, the cells for each
stimulant group were harvested, pooled and transferred to a FACS
tube, washed in PBS plus 1% BSA and stained with anti-CD3-
PerCP (BD Pharmingen), anti-CD4-PacificBlue (BD Pharmingen),
anti-CD8-PacificOrange (Caltag), anti-CD45RO-Alexa700 (Bio-
legend) and UV Viability dye (Invitrogen). The cells were washed,
fixed, and permeabilized with the Cytofix/Cytoperm kit (BD
Pharmingen), and stained with anti-IFN-c-FITC (BD Pharmin-
gen), anti-IL2-Allophycocyanin (BD Pharmingen), and anti-TNF-
a-PECy7 (BD Pharmingen). Cells were analyzed using 9-color
panels on an LSRII (Becton-Dickinson). Data were analyzed using
the FlowJo (Tree Star) software. The frequency of cytokine-
producing CD4
+ T cell subsets in the medium control cultures
were subtracted from the corresponding values for the CD4
+ T cell
subsets in the cultures containing Ag.
Ab ELISA
Ab to CSP were determined by evaluating IgG responses to the
Pf CSP R region as measured using standard ELISA with R32LR
as the capture Ag and reported in mg/ml [16,17,18].
Statistical Analyses
Prior to statistical analysis any values from the intracellular
cytokine staining assay that were less than or equal to zero were
adjusted to 0.001. Statistical analyses were performed using
GraphPad Prism 4.03 for Windows (GraphPad Software). Groups
were compared using the two-tailed Mann Whitney U test. For the
data presented in Figure 7, variables were log transformed due to
the non-normality of the untransformed data as well as the range
(over 3000 fold) of the untransformed data. Spearman’s rank
IL-2
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agreement between the log of IgG level and log of the percentage
of T cells expressing IL-2.
Results
PBMC from RTS,S/AS-immunized subjects contain readily
detectable populations of CD4
+ TE/EM and CD4
+ TCM cells
PBMC collected at baseline and at each time point after vac-
cination and challenge were stimulated for 18 h with 2 contiguous
34 and 44-mer CSP peptides and CD4
+ T cells were then
analyzed for the expression of phenotypic surface markers indi-
cative of memory subsets. CD45RO
+ CD4
+ T cells were further
subdivided into CCR7
+ TCM and CCR7
2 TE/EM subsets (Fig. 1A).
Because it is conceivable that stimulation with antigen in vitro may
have induced some CCR7
+ TCM cells to differentiate into CCR7
2
TE/EM cells, and Brefeldin A has been shown to interfere with
CCR7 expression on activated CD4
+ T cells [15], we included the
fluorescently-labeled CCR7-specific antibodies in the culture
medium to capture the CD4
+ T cell phenotype prior to antigen
stimulation. In addition, the short culture period most likely
minimized the possibility of in vitro differentiation from a CCR7
+
to a CCR7
2 T cell subset. The frequencies of CD4
+ TCM (mean
32%; range 11–58%) and TE/EM cells (mean 9%; range 2–35%)
cells were constant for each specific individual over the course of
the study. Once we identified the CD4
+ TE/EM and TCM cell
subsets, we then characterized their cytokine production to
determine the relative contribution of each subset to protective
immunity.
Protected volunteers generate higher frequencies of IL-2-
producing CD4
+ TE/EM and CD4
+ TCM cells than non-
protected volunteers
In our previous study [8] we showed that the frequency of
CD40L
+CD4
+ T cells producing IL-2 was higher than those
producing TNF-a and IFN-c. Therefore, to confirm and extend
these results we began our study by examining the capacity of
CD4
+ TE/EM and TCM cells to produce IL-2. A typical
intracellular staining to detect IL-2, as well as TNF-a and IFN-c
in the CD4
+ T cell subsets is shown in Figure 1B; Figure 1C shows
the Boolean gating analysis to divide cytokine-producing cells into
seven distinct populations based on their production of IL-2, TNF-
a and IFN-c in any combination. The cumulative results for IL-2-
producing CD4
+ TCM and TE/EM cells from all of the subjects are
shown in Figure 2. The frequency of CSP-specific, IL-2-producing
CD4
+ TCM and TE/EM cells from all time points after vaccination
and challenge was significantly higher than the corresponding
frequency of cells observed at pre-immunity. Notably, the
frequencies of the IL-2 producing CD4
+ TE/EM and TCM cells
from protected subjects were also significantly higher than the
corresponding frequencies of cells from the non-protected subjects
at most of the time points examined, and the difference was most
apparent on the DOC. A study by Sallusto and colleagues [12]
demonstrated that CD4
+ TCM cells responding to polyclonal
stimulation produce moderately greater amounts of IL-2 than
CD4
+ TE/EM cells. By contrast, in the present investigation, we
show that the percentage of TE/EM cells producing IL-2 in
response to CSP peptide stimulation was 2 to 6 fold greater than
the percentage of TCM cells (Fig. 3). Differences were statistically
significant for both protected and non-protected individuals at all
time points. However, as noted in Figure 1, TCM were more
abundant than TE/EM.
Having determined that the frequencies of CS protein-specific
IL-2
+ CD4
+ TCM and IL-2
+ CD4
+ TE/EM cells were higher for
protected compared to non-protected subjects, we asked whether
the total numbers of these cells would also be higher in the
protected group. Using the total blood lymphocyte counts
obtained on the DOC and the frequencies of each cell subset
determined by flow cytometry after in vitro stimulation with the 2
CSP peptides, we were able to calculate the total number of cells
for each subset per microliter of blood. As shown in Table 1, the
total number of CD4
+ TCM cells and of CD4
+ TE/EM cells capable
of producing IL-2 in response to CSP peptides were significantly
higher (p,0.003 CD4
+ TCM;p ,0.015 CD4
+ TE/EM) in protected
as compared to non-protected subjects. Hence, not only the
frequencies, but also the total numbers of CSP-specific IL-2
+
CD4
+ TCM and IL-2
+ CD4
+ TE/EM cells correlated with protection.
Finally, we asked whether the percentage of subjects generating
an IL-2 response significantly above the corresponding pre-
immune level was comparable for protected and non-protected
subjects. For the purpose of this analysis, a positive post-immune
response was defined as being at least 2-fold higher than the
corresponding pre-immune value, and at least 2 SD above the
group mean of the values for the pre-immune samples. The results
showed that the percentage of subjects that manifested a response
on the DOC was significantly higher for protected (P) as compared
to non-protected (NP) subjects for both CD4
+ TE/EM cells (97% (P)
vs. 62% (NP); p=0.0007) and CD4
+ TCM cells (86% (P) vs. 47%
(NP); p=0.0006). These differences were not significant for the
post-second immunization cells but there was a strong trend
(p=0.052) for the 2 month post-challenge CD4
+ TE/EM cells.
There was, however, no significant difference between the mean
frequencies of DOC IL-2
+ CD4
+ T cells from the responding
protected and non-protected subjects.
On the DOC protected subjects have a higher frequency
of TNF-a
+ CD4
+ TE/EM cells than non-protected subjects
IL-2 is generally thought to be a growth promoting cytokine
whereas effector cytokines such as TNF-a and IFN-c are thought
to mediate parasite killing. Therefore, we also investigated the
relative frequencies of TNF-a producing CD4
+ TE/EM and TCM
subsets and the extent to which these frequencies correlate with
protection. Both the CD4
+ TCM and the TE/EM cells from pro-
tected and non-protected subjects developed a TNF-a response
upon stimulation with CSP peptides, and on the DOC, the pro-
tected subjects had a higher frequency of the TNF-a
++ CD
+TE/EM
cells than the non-protected subjects (Fig. 4). The frequency of the
CD4
+ TE/EM cells producing TNF-a was much greater than that
of the CD4
+ TCM cells (Fig. 4) and these differences were most
pronounced for the protected subjects on the DOC. Moreover, as
shown in Table 1, there was also a strong trend (p,0.06) toward a
higher total number of CSP-specific TNF-a
+ CD4
+ TE/EM cells in
the protected as compared to the non-protected subjects. Finally,
as was observed for the IL-2
+ CD4
+ T cells, the percentage of
subjects elaborating a positive DOC TNF-a
+ CD4
+ TE/EM cell
response was significantly higher (p=0.017) for the protected as
compared to the non-protected subjects.
Only CD4
+ TE/EM cells make measurable IFN-c responses
We also measured the frequency of IFN-c-producing memory
CD4
+ T cell subsets and found that only IFN-c
+ TE/EM cells had a
post-vaccination frequency, which exceeded that observed at
baseline (Fig. 5). Although the mean frequencies of CD4
+ TE/EM
cells producing IFN-c were relatively low, 15% of volunteers
exhibited frequencies of IFN-c
+ TE/EM cells ranging between
0.1% to 2.8% of the total CD4
+ TE/EM population, for both post
2
nd and post 3
rd vaccination time points. Under no conditions,
however, did we observe a significant difference between the mean
IL-2
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PLoS ONE | www.plosone.org 3 July 2011 | Volume 6 | Issue 7 | e20775Figure 1. Identification of RTS,S vaccine-induced CSP-specific CD4
+ T cell memory subsets. PBMCs from an RTS,S-immunized volunteer
were stimulated in vitro for 18 h with anti-CD28 and anti-CD49d plus a pool of 2 long contiguous CSP peptides in the presence of PE-conjugated anti-
CCR7 Ab. Cells were harvested and surface-labeled for CD3, CD4, CD8, CD45RO and UV viability dye and then stained intra-cellularly for IL-2, TNF-a
and IFN-c. Cells were acquired on an LSR-II flow cytometer and analyzed using FlowJo. (A) Gating strategy used to identify CD4
+CD45RO
+CCR7
+ TCM
and CD4
+CD45RO
+CCR7
2 TE/EM cells. Numbers indicate the percentage of cells in each gate. (B) Detection of IL-2, TNF-a and IFN-c production by
CD4
+ TCM and CD4
+TE/EM cells. Numbers indicate the percentage of cytokine
+ cells for each memory cell type. (C) Boolean gating analysis was used to
divide cytokine-producing cells into seven distinct populations based on their production of IL-2 (2), TNF-a (T) and IFN-c (G) in any combination. Each
population is shown as two dot plots: the upper is TNF-a vs IL-2 and the lower is IFN-c vs. IL-2. Numbers indicate the percentage of cytokine
+ cells for
each memory subtype.
doi:10.1371/journal.pone.0020775.g001
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PLoS ONE | www.plosone.org 4 July 2011 | Volume 6 | Issue 7 | e20775Figure 2. Frequency of CD4
+ TCM and CD4
+ TE/EM cells producing IL-2 upon recall with CSP peptides. PBMC were obtained at the Pre,
Po2, DOC and PoCh timepoints from RTS,S-immunized subjects and were incubated for 18 h with co-stimulants (medium control) or co-stimulants
plus a pool of 2 long contiguous CSP peptides as described in Methods. Cultures also contained PE-conjugated-CCR7-specific Ab to detect CCR7
+
cells. Cells were harvested and surface-labeled for CD3, CD4, CD8 and CD45RO and then stained for intracellular detection of IL-2, TNF-a and IFN-c
(see Methods and Fig. 1). Cells were analyzed on an LSR-II flow cytometer to identify IL-2-producing CCR7
+CD45RO
+CD4
+ TCM cells and
CCR7
2CD45RO
+CD4
+ TE/EM cells. The frequency of IL-2-producing CD4
+ T cell subsets in the medium control cultures were subtracted from the
corresponding values for the CD4
+ T cell subsets in the cultures containing Ag. The resulting adjusted values are plotted as [A] the % IL-2
producing CD4
+ TCM cells and [B] the % IL-2 producing CD4
+ TE/EM cells for protected (closed symbol) and non-protected (open symbol) subjects.
Statistically significant differences between pre-immune and post-vaccination time points are indicated at the top of the graph. Statistically
significant differences between values for protected and non-protected subjects are as indicated within the body of the graph. *p,0.05; **p,0.01;
***p,0.001.
doi:10.1371/journal.pone.0020775.g002
IL-2
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+ CD4
+ TE/EM cells from protected vs. non-
protected volunteers.
Protected subjects have a higher frequency of IL-2
+ TNF-
a
+ CD4
+ T cells than non-protected subjects
There is some evidence that poly-functional T cells, i.e., cells
producing IL-2 plus one or more effector cytokines, are more
efficient at eliminating cellular pathogens than cells producing only
one cytokine [19,20]. Similarly, we previously demonstrated [8]
that the frequency of RTS,S-induced CSP peptide-reactive CD4
+
T cells producing any two immune markers amongst CD40L, IL-
2, TNF-a or IFN-c, was significantly higher on the DOC in
protected subjects as compared to non-protected subjects. There-
fore, we measured the relative frequencies of memory CD4
+ T cell
subsets capable of producing multiple cytokines. The frequencies
of IL-2
+ IFN-c
+ or TNF-a
+ IFN-c
+ CD4
+ T cells from protected
subjects did not differ significantly from those of non-protected
subjects (data not shown). As shown in Figure 6, the frequencies of
IL-2
+ TNF-a
+ TE/EM and TCM cells from both protected and non-
protected subjects were, at all time points, significantly higher than
the corresponding pre-immune backgrounds. In addition the
frequency of IL-2
+ TNF-a
+ CD4
+ TE/EM cells observed on the
DOC and of IL-2
+ TNF-a
+ CD4
+ TCM cells observed PoCh were
significantly higher in protected vs. non-protected subjects.
The frequency of CSP-specific, IL-2 producing CD4
+ T fells
correlates with CSP R region-specific Ab titers
It is conceivable that the IL-2 producing CD4
+ T cells could
provide help to promote the differentiation of CSP R region-
specific B cells into Ab-producing plasma cells. For example,
Figure 3. Frequency of CD4
+ TCM and CD4
+TE/EM cells producing IL-2 upon recall with CSP peptides. PBMC obtained at the indicated
time points from RTS,S-immunized subjects were incubated as described for Fig. 2 with CSP peptides as described in Methods. Cells were then
analyzed as described in the legend to Fig. 1. The values are plotted as the frequency of IL-2-producing CD4
+ TCM cells (open bars) and IL-2-producing
CD4
+ TE/EM cells (closed bars) for protected (right-hand panels) and non-protected (left-hand panels) subjects. Error bars indicate 95% confidence
intervals. *p,0.05; **p,0.01; ***p,0.001.
doi:10.1371/journal.pone.0020775.g003
Table 1. Number of cells per subset on the DOC.
Cell Subset
a Protected
b (n=29) Non-protected
b (n=47) P value
c
White cells 60836307 55366293 0.051
Lymphocytes 1754684 1725675 0.68
CD3
+ 1412679 1390657 0.78
CD4
+ 912661 849639 0.49
CD4
+ TCM 279628 298616 0.27
IL-2
+ 0.29760.042 0.17360.026 0.003
TNF
+ 0.06860.019 0.05360.012 0.33
IFN-c
+ 0.02660.007 0.02860.006 0.79
Double Cytokine ( IL-2
+TNF
+) Producing TCM 0.05860.015 0.03660.009 0.16
CD4
+ TE/EM 0.7560.077 0.9360.077 0.10
IL-2
+ 0.32660.063 0.16660.025 0.015
TNF
+ 0.08560.022 0.04760.010 0.062
IFN-c
+ 0.05860.018 0.05160.023 0.33
Double Cytokine ( IL-2
+TNF
+) Producing TEM 0.06460.018 0.03260.005 0.13
aper ml of peripheral blood.
bmean 6 SEM.
cMann-Whitney U-test.
doi:10.1371/journal.pone.0020775.t001
IL-2
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PLoS ONE | www.plosone.org 6 July 2011 | Volume 6 | Issue 7 | e20775Litjens et al [21] recently demonstrated a correlation between
HBsAg-specific IL-2-producing memory T cells and the genera-
tion of IgG-secreting plasma cells. To investigate if the level of
CSP R region-specific B cell responses were associated with the
magnitude of RTS,S-induced IL-2
+ CD4
+ T cells, we performed
statistical calculations using Spearman’s regression analysis that
integrates the levels of CSP R region-specific serum Ab of each
volunteer with the corresponding frequency of IL-2 producing
CD4
+ TE/EM and TCM cells. The results (Fig. 7) show statistically
significant correlations between the frequency of IL-2 producing
CD4
+ T cells and Ab responses for TE/EM Po2 (Rs=0.26;
p=0.03) and DOC (Rs=0.27; p=0.02) and for TCM Po2
(Rs=0.35; p=0.003). There was also, albeit weaker, correlation
between the frequency of IL-2
+TNF-a
+ CD4 T cells and Ab
production (data not shown) but no correlation was observed
between Ab levels and total TNF-a
+ CD4
+ T cells.
Figure 4. Frequency of CD4
+TCM and TE/EM cells producing TNF-a upon recall with CSP peptides. PBMC were obtained at the indicated
time points from RTS,S-immunized subjects and were incubated as described in Fig. 3 with CSP peptides as described in Methods. Cells were then
analyzed as described in the legend to Fig. 1. The values are plotted as [A] the % TNF-a-producing CD4
+ TCM cells and [B] the % TNF-a-producing
CD4
+ TE/EM cells for protected (closed symbol) and non-protected (open symbol) subjects. Statistically significant differences between pre-immune
and post-vaccination time points are indicated at the top of the graph. Statistically significant differences between values for protected and non-
protected subjects are as indicated within the body of the graph. *p,0.05; **p,0.01; ***p,0.001.
doi:10.1371/journal.pone.0020775.g004
IL-2
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Ag-specific immunologic memory is one of the cardinal features
of the immune response and the maintenance of long-lived
memory T and B cells is inextricably linked to protracted
protective immunity because these memory cells are able to
generate a prompt and robust response upon re-encounter with
Ag. It has been amply demonstrated in several vaccine systems
that long-term protection is often maintained by subsets of
memory T cells including TE/EM cells that rapidly produce
cytokine upon re-exposure to Ag and TCM cells that have the
additional property of being able to undergo homeostatic
proliferation in order to maintain the memory pool [1]. The
results from our present study demonstrate that RTS,S-induced
Figure 5. Frequency of CD4
+ TCM and CD4
+TEM cells producing IFN-c upon recall with CSP peptides. PBMC were obtained at the
indicated time points from RTS,S-immunized subjects and were incubated as in Fig. 3 with CSP peptides as described in Methods. Cells were then
analyzed as described in the legend to Fig. 1. The resulting values are plotted as the % of [A] IFN-c producing CD4
+ TCM cells and [B] IFN-c producing
CD4
+ TE/EM cells for protected (closed symbol) and non-protected (open symbol) subjects. Statistically significant differences between pre-immune
and post-vaccination time points are indicated at the top of the graph. Statistically significant differences between values for protected and non-
protected subjects are as indicated within the body of the graph. *p,0.05; **p,0.01; ***p,0.001.
doi:10.1371/journal.pone.0020775.g005
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PLoS ONE | www.plosone.org 8 July 2011 | Volume 6 | Issue 7 | e20775PBMC contain both CSP-specific CD4
+ TE/EM and CD4
+ TCM
cells and that both subsets can be re-stimulated in vitro with CSP
peptides to generate strong IL-2 responses. Notably, not only the
frequencies, but also the total number of IL-2-producing CD4
+
TE/EM and CD4
+TCM cells, were higher for protected as com-
pared to non-protected volunteers. This result is in agreement with
our previous findings [8] that CSP peptide-stimulated PBMC from
protected individuals generated a higher frequency of IL-2
+
Elispots than PBMC from non-protected individuals as well as a
higher frequency of CSP-specific CD4
+ T cells expressing two or
more of the CD40L, IL-2, TNF-a and IFN-c biomarkers. The
percentage of subjects generating a positive DOC IL-2
+ CD4
+ T
cell response was also significantly higher for protected versus non-
protected subjects. The lack of responsiveness in some subjects
Figure 6. Frequency of CD4
+ TCM and TE/EM cells producing both IL-2 and TNF-a upon recall with CSP peptides. PBMC were obtained at
the indicated time points from RTS,S-immunized subjects and were incubated as described in Fig. 3 with CSP peptides as described in Methods. Cells
were then analyzed as described in the legend to Fig. 1. The values are plotted as the % [A] CD4
+ TCM cells producing both IL-2 and TNF-a and [B]
CD4
+ TE/EM cells producing both IL-2 and TNF-a for protected (closed symbol) and non-protected (open symbol) subjects. Statistically significant
differences between pre-immune and post-vaccination time points are indicated at the top of the graph. Statistically significant differences between
values for protected and non-protected subjects are as indicated within the body of the graph. *p,0.05; **p,0.01; ***p,0.001.
doi:10.1371/journal.pone.0020775.g006
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to confer protection to 100% of the vaccinees. Whether these
differences are due to genetic or other factors will require further
investigation.
With regard to effector cytokines, stimulation of CD4
+ TE/EM
cells from protected subjects with CSP peptides induced TNF-a
secretion and once again both the frequency (highly significant)
and the number (strong trend) of these TNF-a-producing CD4
+
TE/EM cells were higher for protected vs. non-protected volun-
teers. By contrast, with the exception of the PoCh time point, the
responses of TNF-a-producing CD4
+ TCM cells did not correlate
with protection. Similarly, CD4
+ TE/EM but not TCM cells
developed a relatively weak IFN-c response, but in no case was
there a correlation with protection.
The observation that the frequency of CD4
+ TE/EM cells
producing IL-2 was higher than the frequency of the correspond-
ing population of CD4
+ TCM cells differs from that of Sallusto et al
[12] who showed that polyclonally activated human CD4
+ TCM
produce higher amounts of IL-2 than CD4
+ T E/EM cells. Other
more recent studies [20] have reported that under certain
conditions, for example, vaccinia stimulation of human virus-
specific CD4
+ T cells, IL-2 is produced predominantly by CD4
+
TE/EM cells. Moreover, Divekar et al [22] demonstrated that
humans immunized with protein vaccines such as tetanus and
diphtheria, also have a higher frequency of IL-2-producing CD4
+
TE/EM cells than IFN-c-secreting TE/EM cells. Seder et al [5] have
proposed a linear differentiation model for CD4
+ T cells in which
naı ¨ve T cells proceed along a pathway that begins with CD4
+ TCM
cells producing only IL-2 or TNF-a followed by TCM cells that
produce both IL-2 and TNF-a and subsequently by cells that
begin to also produce IFN-c. They further state that this model is
most evident following vaccination with protein plus adjuvant. It is
conceivable, therefore, that CD4
+ TE/EM cells from persons
vaccinated with a protein Ag such as RTS,S produce predomi-
nately IL-2 on the DOC because they might be only at the initial
stages of the contraction phase. Alternatively, it should be
emphasized that our analyses were performed on peripheral blood
cells that may include re-circulating TCM cells that have transiently
down-regulated CCR7 in order to leave the lymph node and enter
the blood stream.
Figure 7. CSP-specific IL-2
+ TE/EM and TCM CD4
+ T cells correlate with anti-CSP R region Ab titers. The figures display the log base 10 of
the IgG level in micrograms per milliliter versus log of the percent of T cells expressing IL-2 as assayed by flow cytometry. Individuals who were
protected from malaria by vaccination are noted with filled circles, while those not protected by open circles. The figure also shows the Spearman’s
correlation between the log IgG and log percent cells for the combined protected and non-protected individuals as well as a trend line.
doi:10.1371/journal.pone.0020775.g007
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PLoS ONE | www.plosone.org 10 July 2011 | Volume 6 | Issue 7 | e20775In the present study, IL-2 was the predominant cytokine
produced by both memory phenotype CD4
+ T cells upon Ag
recall in vitro and both the frequencies and the numbers of the IL-
2
+ CD4
+ TCM and TE/EM cells also correlated strongly with
protection. There are several mechanisms that might explain the
latter observation. For example, IL-2 could act as an autocrine or
paracrine growth factor to promote the expansion of cells pro-
ducing effector cytokines such as TNF-a. We showed previously
that IL-2-producing CD4
+ T cells also express CD40L [8] and
hence they may have promoted a protective immune response by
licensing DCs to produce cytokines and by inducing the dif-
ferentiation of B cells through CD40L-CD40 interactions [23]. We
have also demonstrated recently that CSP R region-specific Abs
make a strong and significant contribution to RTS,S-induced
protection [8] and IL-2, therefore, might contribute to protection
by directly promoting the growth and differentiation of R region-
specific B cells [21,24]. Similarly, IL-2 may act as a growth factor
for follicular Th cells that induce B cells to undergo rapid
proliferation and hence drive the germinal center reaction [23]. In
support of this mechanism, the results in Figure 7 demonstrate a
direct correlation between the frequency of IL-2-producing CD4
+
T cells and the titers of CSP R region-specific antibodies in the
same individual. In agreement with this, Galli et al [25] also
reported recently that immunization of humans with an avian
influenza vaccine in the MF59 adjuvant induces virus-specific
CD4
+ T cells that produce primarily an IL-2
+ IFN-c
2 phenotype.
In addition, the frequency of virus-specific total CD4
+ T cells
induced with one dose of vaccine predicted the rise and long-term
maintenance of neutralizing antibodies after booster immunization.
The result in the present study differs, however, from that
reported previously [8], which found no correlation between
RTS,S-induced humoral and cellular responses. Several factors
might provide at least a partial explanation for this discrepancy. In
the previous study, we used the total frequency of CD4
+ T cells
expressing any two of the CD40L, IL-2, TNF-a and IFN-c
biomarkers in the antibody correlation studies, whereas in the
present study we considered only IL-2 responses. The discrepancy
could also be due to the use of different culture conditions
including cell densities and antigens, (15-mer versus 35-mer and
40-mer peptides), used for in vitro re-stimulation. We also analyzed
the combined effect of both antibody and frequency of IL-2
+
CD4
+ T cells as a potential correlate of protection, but there was
no increase in correlation relative to that obtained with antibody
alone (data not shown). This was likely due to the already very
strong correlation of antibody levels with protection.
The current results also show that both the frequency and the
number (strong trend) of CD4
+ TE/EM cells producing TNF-a were
higher on the DOC in protected vs. non-protected subjects. This
finding is in agreement with previous reports [26,27] that TNF-a
can suppress the growth of exo-erythrocytic forms of the malaria
parasite in vitro [28] and in vivo [26,27]. There is also evidence [19]
that poly-functional T cells producing more than one cytokine
provide greater protection against infection than T cells secreting
only one cytokine. In the present study, we also identified a
population of CD4
+ TE/EM cells that were producing both IL-2 and
TNF-a and the frequency of these cells on the DOC also correlated
with protection. It is conceivable that IL-2 was acting as an
autocrine growth factor to drive the expansion of these cells, while
TNF-a was mediating their effector function. These results are also
very similar to those of Huaman et al [29] who examined cytokine
responses by CD4
+ T cells in humans immunized three times with
the malaria antigen AMA-1formulated in Alhydrogel. As in our
study, they found that the highest frequency of AMA-1-specific,
multifunctional CD4
+ T cells were IL-2
+TNF-a
+ double producers
and they further demonstrated that the frequency of IL-2 sin-
gle producers increased after immunization. Similarly, they also
detected both TCM and TEM cells even as early as 7 days after the
primary immunization, although they did not characterize cytokine
production by these cells. In the present study, it is noteworthy that
the correlation of protection with the frequency of CD4
+ T cells
making TNF-a (Fig. 4) shifted from CD4
+ TE/EM cells at the DOC
to CD4
+ TCM cells at 2 mo PoCh. A similar shift was also observed
for CD4
+ T cells producing both IL-2 and TNF-a (Fig. 6). It is likely
that on the DOC there was still an abundance of CSP-specific
effector-like cells capable of elaborating TNF-a to protect against
the parasite. By contrast, by 2 mo PoCh, CD4
+ TCM cells would
likely exceed the number the effector-like cells and hence be the
more critical population capable of differentiating into mediators of
protection. A similar conclusion regarding the key role of central
memory T cells was reported previously by Keating et al [30] who
studied cultured Elispot cytokine responses using PBMC from
donors immunized in a prime-boost regimen with the malaria
{multi-epitope plus TRAP} antigen.
The results of both this and our previous study [8] demonstrate
that IL-2 is the predominant cytokine elaborated by RTS,S-
induced CD4 T cells upon in vitro recall with CSP peptides. By
contrast, only CD4
+ TE/EM cells from a small percentage of
volunteers produced IFN-c in response to CSP peptides. This is in
agreement with other reports [12,13,14] that CD4
+ TE/EM cells
are the main producers of effector cytokines such as IFN-c. The
present IFN-c results differ, however, from our previously pub-
lished studies [8,31]. In the most recently published study we
demonstrated that the frequency of CD4
+ T cells expressing IFN-c
plus another biomarker (eg. CD40L) was higher in protected than
in non-protected subjects [8]. The reasons for this discrepancy is
unclear, but may be due to the use of different biomarkers (CCR7
vs. CD40L) and different culture conditions, as described above
(vide ante). In the present study we added CCR7-specific Ab
directly to the cell cultures. Other investigators have reported [15]
adding CCR7-specific Ab to cultures and demonstrating that the
proportion of CCR7
+ and CCR7
2 CD4
+ T cells producing IL-2
and IFN-c following SEB stimulation was similar to those detected
in subsets purified by cell sorting. In addition, we also measured
post re-challenge IFN-c production by total CD4
+ T cells from
one subject in the presence and absence of anti-CCR7 and found
that the magnitude of the IFN-c response in the presence of anti-
CCR7 was 81% of the analogous responses in the absence of anti-
CCR7. Consequently, the presence of anti-CCR7 did not appear
to markedly interfere with the IFN-c response of the cultured
CD4
+ T cells. In the study by Sun et al [31], apart from different
culture conditions, the RTS,S was administered according to a
different regimen of vaccination, 0, 1 and 7 months, which might
have generated stronger CSP peptide-specific IFN-c
+CD4
+ and
CD8
+ T cell responses.
Thirty two subjects from the present RTS,S vaccine trial were
protected against the primary challenge; 18 subjects returned for a
re-challenge 5 months after the initial challenge, and 8/18 were
protected against the secondary challenge. At the day of re-
challenge, the frequency of CD4
+ T cells capable of generating an
IL-2 recall response no longer correlated with protection. This
result is in agreement with the previous finding [8] that on the day
of re-challenge only CS protein-specific CD4
+ T cells expressing
IFN-c plus one other biomarker had higher levels in protected
than in the 5 out of 10 non-protected subjects analyzed. The lack
of correlation for IL-2 may have been due to the low number of
subjects participating in the re-challenge. In addition, at this
much later time point, alternative populations of cells and / or
mechanisms may have been involved in mediating protection.
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PLoS ONE | www.plosone.org 11 July 2011 | Volume 6 | Issue 7 | e20775In summary, PBMC from RTS,S/AS vaccinated subjects
contained both CD4
+ TCM and CD4
+ TE/EM cells that could be
re-called in vitro with CSP peptides to generate strong IL-2 responses.
Both the frequency and the total number of memory CD4
+ Tc e l l s
producing IL-2 correlated with protection, indicating that IL-2 may
promote B cell and effector T cell responses. In support of this notion,
the frequency of IL-2-producing memory CD4
+ T cells correlated
with the CSP-specific Ab titers within corresponding individuals.
Immunization with RTS,S/AS also induced a higher frequency of
TNF-a producing CD4
+TE/EM cells in protected as compared to
non-protected subjects. Consequently, TNF-a likely also contributes
to RTS,S/AS-induced protective immunity.
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